Sirtuin 1: A Dilemma in Transplantation

Table 1

Sirtuin 1 effects on T cell subsets.

Treg	Sirt1 stabilizes Notch1 intracellular domain proximal to the membrane ⟶ promotes Treg cells survival and function (29); Sirt1 deletion or silencing by splitomicin and EX-527 ⟶ prolonged cardiac allograft survival in a Treg-dependent manner (11); Sirt1 CD4 conditional deletion of Sirt1 (Sirt^fl/flCD4^cr) or EX-527 administration ⟶ improved renal allograft outcome (30); Sirt1 inhibition by sirtinol in heart TX⟶ increased proportion of Treg cells (13); Sirt1 inhibition ⟶ decreased Foxp3 polyubiquitination and degradation, increased Foxp3 protein level (31)
Th17	Sirt1 inhibition by sirtinol in heart TX ⟶ reduced percentage of Th17 cells; decreased expression of IL-17A and RORγt transcription factor (13); Sirt1 activation by metformin in tumor⟶ reduced IL-17A secretion and RORγt expression (33)
T CD4+ lymphocytes	Sirt1 deficiency in thymus ⟶ impaired elimination of autoreactive T cells (28); Sirt1 activation by resveratrol ⟶ inhibited T cells activity, reduced cytokines IL-2, IFN-γ, IL-4, and IL-5 production and inhibited c-Jun translocation to the nucleus(12); Sirt1 deletion ⟶ T CD4+ cells proliferation (34); Sirt1 activation by resveratrol ⟶ inhibited T cells activation and improved tolerance (34)

Sirt1: sirtuin 1; TX: transplantation; Th: T helper; IL: interleukin; IFN-γ: interferon-γ